Summarized by Masters of Longevity from Longevity Technology.
A biotech news piece on a tiny peptide immunotherapy candidate aimed at clearing senescent “zombie” cells, and what opening the article will reveal about the approach and next steps.
Key Takeaways
- Immorta’s nine–amino–acid peptide is designed to recruit T cells to clear senescent cells.
- The peptide is presented as a simpler, off‑the‑shelf immunotherapy alternative to existing approaches.
- Immorta plans human testing of SenoMune‑0257 in 2026, with trial details still unspecified.
